Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Revenue projections:

Revenue projections for HUM
Revenue projections for HUM

The projected decline in HUM's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.771000
forwardPE 19.890352
debtToEquity 77.073000
earningsGrowth -0.046000
revenueGrowth 0.235000
grossMargins 0.140060
operatingMargins 0.046710
trailingEps 9.370000
forwardEps 15.340100

HUM's current ratio is 1.771, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting HUM has no trouble covering its short-term financial obligations.
HUM's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
HUM's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting HUM to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for HUM
Price projections for HUM

The stock price of HUM has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.

Insider Transactions:

Insider Transactions for HUM
Insider Transactions for HUM


Humana Inc. saw 2 buy transactions, with market price of 205.81500244140625.During the review period, no buy transactions were executed.HUM has experienced more selling activity at current price levels, which could suggest a bearish outlook. If the trend of increased selling continues, it may result in further price declines for the stock.

Recommendation changes over time:

Recommendations trend for HUM
Recommendations trend for HUM


Recent analysis shows a strong buy bias for HUM, encouraging investors to view it as a solid investment option. The positive sentiment surrounding HUM suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.